DataVXAdvanced MaterialsPaper
journal article·2018-03Open access

Reassembly of 89Zr‐Labeled Cancer Cell Membranes into Multicompartment Membrane‐Derived Liposomes for PET‐Trackable Tumor‐Targeted Theranostics

Bo Yu, Shreya Goel, Dalong Ni, Paul A. Ellison, Cerise M. Siamof, Dawei Jiang, Liang Cheng, Lei Kang, Faquan Yu, Zhuang Liu, Todd E. Barnhart, Qianjun He, Han Zhang, Weibo Cai

Advanced Materials· Volume 30· Issue 13
Publisher pageOpen full text
Source abstract

Abstract

Abstract Nanoengineering of cell membranes holds great potential to revolutionize tumor‐targeted theranostics, owing to their innate biocompatibility and ability to escape from the immune and reticuloendothelial systems. However, tailoring and integrating cell membranes with drug and imaging agents into one versatile nanoparticle are still challenging. Here, multicompartment membrane‐derived liposomes (MCLs) are developed by reassembling cancer cell membranes with Tween‐80, and are used to conjugate 89Zr via deferoxamine chelator and load tetrakis(4‐carboxyphenyl) porphyrin for in vivo noninvasive quantitative tracing by positron emission tomography imaging and photodynamic therapy (PDT), respectively. Radiolabeled constructs, 89Zr‐Df‐MCLs, demonstrate excellent radiochemical stability in vivo, target 4T1 tumors by the enhanced permeability and retention effect, and are retained long‐term for efficient and effective PDT while clearing gradually from the reticuloendothelial system via hepatobiliary excretion. Toxicity evaluation confirms that the MCLs do not impose acute or chronic toxicity in intravenously injected mice. Additionally, 89Zr‐labeled MCLs can execute rapid and highly sensitive lymph node mapping, even for deep‐seated sentinel lymph nodes. The as‐developed cell membrane reassembling route to MCLs could be extended to other cell types, providing a versatile platform for disease theranostics by facilely and efficiently integrating various multifunctional agents.
Source: crossref · Quality: baseline

Research context

NanomaterialsBiomaterials

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National‐Regional Key Technology Engineering Laboratory for Medical Ultrasound Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging School of Biomedical Engineering Health Science Center Shenzhen University Shenzhen 518060 China

Departments of Radiology and Medical Physics University of Wisconsin–Madison Madison WI 53705 USA

Key Laboratory for Green Chemical Process of Ministry of Education School of Chemical Engineering and Pharmacy Wuhan Institute of Technology Wuhan 430205 China

Institute of Functional Nano & Soft Materials (FUNSOM) Collaborative Innovation Center of Suzhou Nano Science and Technology Soochow University Suzhou 215123 China

Department of Nuclear Medicine Peking University First Hospital Beijing Beijing 100000 China

Shenzhen Engineering Laboratory of Phosphorene and Optoelectronics Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province College of Optoelectronic Engineering Shenzhen University Shenzhen 518060 P. R. China

University of Wisconsin Carbone Cancer Center University of Wisconsin–Madison Madison WI 53705 USA

Funding

National Natural Science Foundation of China · National Institutes of Health · American Cancer Society

References (38)

Show source-provided references
1. 10.1038/nnano.2012.23710.1038/nnano.2012.237 ↗
2. 10.1021/acs.nanolett.5b0434310.1021/acs.nanolett.5b04343 ↗
3. 10.1002/smll.20150238810.1002/smll.201502388 ↗
4. 10.1021/cr300143v10.1021/cr300143v ↗
5. 10.1021/acs.chemrev.5b0014810.1021/acs.chemrev.5b00148 ↗
6. 10.1002/adma.20160620910.1002/adma.201606209 ↗
7. 10.1016/j.biomaterials.2017.02.04110.1016/j.biomaterials.2017.02.041 ↗
8. 10.1002/adma.20130063810.1002/adma.201300638 ↗
9. 10.1002/adhm.20120013810.1002/adhm.201200138 ↗
10. 10.1021/nn503779d10.1021/nn503779d ↗
11. 10.1021/acs.nanolett.6b0278610.1021/acs.nanolett.6b02786 ↗
12. 10.1021/nl500618u10.1021/nl500618u ↗
13. 10.1021/acs.bioconjchem.5b0057210.1021/acs.bioconjchem.5b00572 ↗
14. 10.1002/smll.20150238810.1002/smll.201502388 ↗
15. 10.1021/acs.nanolett.6b0278610.1021/acs.nanolett.6b02786 ↗
16. 10.1038/nnano.2012.21210.1038/nnano.2012.212 ↗
17. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
18. 10.1073/pnas.150966711210.1073/pnas.1509667112 ↗
19. 10.1002/anie.20161064910.1002/anie.201610649 ↗
20. 10.1038/nnano.2014.13010.1038/nnano.2014.130 ↗
21. 10.1038/nrurol.2016.2610.1038/nrurol.2016.26 ↗
22. 10.1002/jps.1021610.1002/jps.10216 ↗
23. 10.1021/acs.analchem.5b0209610.1021/acs.analchem.5b02096 ↗
24. 10.1016/j.ijpharm.2017.06.05910.1016/j.ijpharm.2017.06.059 ↗
25. 10.1038/nbt.333010.1038/nbt.3330 ↗
26. 10.1039/C6SC04128K10.1039/C6SC04128K ↗
27. 10.1021/jm500389b10.1021/jm500389b ↗
28. 10.1021/acsnano.5b0052610.1021/acsnano.5b00526 ↗
29. 10.1021/acsnano.7b0153010.1021/acsnano.7b01530 ↗
30. 10.1021/acs.bioconjchem.5b0057210.1021/acs.bioconjchem.5b00572 ↗
31. 10.1021/acs.molpharmaceut.6b0013210.1021/acs.molpharmaceut.6b00132 ↗
32. 10.1021/acs.molpharmaceut.6b0037210.1021/acs.molpharmaceut.6b00372 ↗
33. Goins B. · J. Nucl. Med. · 1996 · 37 · 1374
34. 10.1021/acsnano.6b0307410.1021/acsnano.6b03074 ↗
35. Noguti J. · Cancer Genomics Proteomics · 2012 · 9 · 329
36. 10.1002/smll.20160169610.1002/smll.201601696 ↗
37. 10.1159/00035209210.1159/000352092 ↗
38. 10.1371/journal.pone.013571410.1371/journal.pone.0135714 ↗